Navigation Links
Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
Date:8/7/2012

tting."

About High-Grade GliomaHigh-grade gliomas are the most common and most aggressive primary brain tumors. Prognosis for patients with high-grade gliomas remains poor with estimated median survival of 12 to 18 months. Recurrence after initial therapy with temozolomide and radiation is nearly universal. Since May 2009, the majority of patients in the U.S. with an initial recurrence of high-grade glioma receive bevacizumab. Bevacizumab has response rates from 32-62% and has improved median overall survival in patients with recurrent high-grade gliomas.1 However, the response is short lived and nearly 100% of patients eventually progress despite bevacizumab. No chemotherapeutic agent administered following progression through bevacizumab has made a significant impact on survival.2,3 Patients progress to death within 1-5 months after resistance develops.3,4 Patients with high-grade gliomas who have progressed through bevacizumab represent a population in dire need of new therapies.

About Etirinotecan PegolEtirinotecan pegol is a unique, targeted topoisomerase I inhibitor designed for prolonged tumor cell exposure. Etirinotecan pegol is believed to penetrate the vasculature of the tumor environment more readily than normal vasculature, increasing the concentration of active drug within tumor tissue to enhance anti-tumor activity.  The BEACON study is a Phase 3 clinical study currently evaluating etirinotecan pegol for the treatment of metastatic breast cancer.   In addition, etirinotecan pegol is also being tested as a single agent in a Phase 2 clinical trial in patients with platinum-refractory/resistant ovarian cancer, a Phase 2 clinical trial in patients with colorectal cancer with KRAS mutations after failing first- line therapy, and a Phase 1 clinical trial evaluating etirinotecan pegol in combination with 5-FU and leucovorin therapy.

About NektarNektar Therapeutics is a biopharmaceutical company
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... SUNNYVALE, Calif. , June 19, 2013 ... today announced that The New England Journal of ... a Phase 1b/2 study evaluating the investigational oral Bruton,s ... chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ... patients with relapsed/refractory CLL or SLL, even in patients ...
(Date:6/19/2013)... CHICAGO , June 19, 2013 The Physician-Patient ... reduce alarm fatigue. The need to urgently address ... in its Sentinel Event Alert #50 , "Medical device alarm ... Alert database, between January 2008 and June 2012, there were ... 80 resulted in death (82%) , 13 resulted in ...
(Date:6/19/2013)...   Voices Against Brain Cancer (VABC), a ... cancer, today announced that it has awarded Tocagen Inc. ... investigation of Toca 511 & Toca FC in patients ... (Grade 3 or Grade 4).  Tocagen is a privately ... with an initial focus on brain cancer. ...
Breaking Medicine Technology:Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3
(Date:6/19/2013)... (PRWEB) June 19, 2013 The ... program is this Friday, June 21 at midnight ... ongoing programs and innovative people who’ve raised the ... information, visit http://www.minonline.com/ima . , Any consumer ... magazine title is eligible to enter. Additionally, advertising ...
(Date:6/19/2013)... Utah (PRWEB) June 19, 2013 Today, ... Wisconsin Health Insurance Exchange . Zane Benefits, which provides ... benefits, is the leader in defined contribution ... to Zane Benefits’ website, as part of the Affordable ... small businesses will become available through new state health ...
(Date:6/19/2013)... The Journal of Parasitology – Although ... software, it creates questions of ethics. For scientific publications, ... already published case shows, scientific publications need clear guidelines ... Journal of Parasitology features a commentary on ... article published in the Journal of the New York ...
(Date:6/19/2013)... Pa. (June 19, 2013) The results of three ... of Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... study indicates that continuous "machine learning" using artificial neural ... in patients with advanced brain cancers. Another study in ...
(Date:6/19/2013)... early April, senior leaders from medical, law enforcement, military, ... one question: how can first responders improve survival after ... results of this discussion are now available in " ... ," a concept paper published in the June issue ... Acute Care Surgery , official publication of the ...
Breaking Medicine News(10 mins):Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... are supporting WaterAid to deliver the most wished for Christmas present in ... ... Bendalls are appealing to social media groups, the Australian blog community and ... donate and download a e-Christmas Card , with a personalized message. ...
... scientists and the news media have evolved tremendously over ... improve communications with both the media and the lay ... commentary appears this month in a major scientific journal. ... and pharmacology at Wake Forest University School of Medicine, ...
... white women to have reconstruction after mastectomy , , MONDAY, ... women are more likely to have immediate breast reconstruction ... , This is also true for more educated women ... black women and those who live in predominantly black ...
... found little link between drinking and malignancies , , MONDAY, ... your chances of developing cancer after age 65, new ... lack of physical activity were among the usual suspects ... to the Duke University study. , The findings are ...
... nanoparticles and polymer carriers as potential new techniques ... and blindness in the United States, according to ... Research Institute Conference. , The report ( http://www.iovs.org/cgi/content/full/49/11/4712 ... for ocular drug delivery to the posterior segment ...
... LAKE CITY Nov. 17, 2008 Researchers at the ... trial that uses a patient,s own stem cells to treat ... Repair Cell Treatment of Patients with Dilated Cardiomyopathy (IMPACT-DCM) study ... (CRC) and their ability to improve heart function. , Patients ...
Cached Medicine News:Health News:Urgent Request for Water 2Health News:Award-winning researcher says relationships with news media, public are critical 2Health News:Award-winning researcher says relationships with news media, public are critical 3Health News:Wealthy More Likely to Have Breast Reconstruction 2Health News:Stay Upbeat, Exercise to Help Prevent Cancer in Old Age 2Health News:Conference report highlights new research into drug delivery to treat eye disease 2Health News:U of U researchers to use patient's own stem cells to treat heart failure 2
Post-Surgical compression garments...
... Albumin Cobalt Binding (ACB®) Test is a ... Albumin (IMA®) by measuring the cobalt binding ... sample. First identified in the early 1990s, ... in contact with ischemic tissue in the ...
... Albumin Cobalt Binding (ACB®) Test is a ... Albumin (IMA®) by measuring the cobalt binding ... sample. First identified in the early 1990s, ... in contact with ischemic tissue in the ...
... menu includes kits that quantitatively measure two ... (a). An elevated serum or plasma homocysteine ... and independent risk factor for cardiovascular disease. ... have associated elevated levels of Lp(a) with ...
Medicine Products: